Ratings Kinnevik AB London S.E.

Equities

0RGZ

SE0022060513

Market Closed - London S.E. Other stock markets 08:55:00 06/06/2024 pm IST			5-day change	1st Jan Change
440 ^SEK	0.00%		+346.25%	+312.01%

14/06	Enveda Therapeutics, Inc. announced that it has received $55 million in funding from a group of investors	CI
05/06	Kinnevik AB Approves Extra Distribution	CI

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

The prospective high growth for the next fiscal years is among the main assets of the company
The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The company appears to be poorly valued given its net asset value.
Analysts covering this company mostly recommend stock overweighting or purchase.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
The opinion of analysts covering the stock has improved over the past four months.
Consensus analysts have strongly revised their opinion of the company over the past 12 months.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.04 times its estimated earnings per share for the ongoing year.
Based on current prices, the company has particularly high valuation levels.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Sector: Investment Holding Companies

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
KINNEVIK AB	+312.01%	2.44B		-
INVESTOR AB	+24.02%	83.58B		A-
INVESTMENT AB LATOUR	+11.70%	17.77B	-	C+
KOÇ HOLDING	+56.56%	17.14B		A
AB INDUSTRIVÄRDEN	+10.37%	14.79B	-	C-
L E LUNDBERGFÖRETAGEN AB	-4.14%	12.36B	-	C
BAJAJ HOLDINGS & INVESTMENT LIMITED	+7.24%	10.95B	-	D
HAL TRUST	-0.53%	10.93B		-
MERITZ FINANCIAL GROUP INC.	+29.44%	10.13B		-
SK SQUARE CO., LTD.	+85.36%	9.44B		B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes